A major scientific advance in protein modeling developed by Microsoft Research AI for Science, has been published in Science.

The model is trained on a massive dataset over 200 milliseconds of molecular dynamics simulations and half a million protein ...

AI meets molecular dynamics in Divamics’ latest breakthroughs, accelerating new therapies for complex metabolic conditions.

Biohaven Ltd. (NYSE: BHVN) is one of the best low priced pharma stocks to buy now. Earlier on June 10, Bexorg Inc., which is ...

Conversations with entrepreneurs, technologists, and researchers on emerging technologies and the importance of STEM in drug discovery.

UC Santa Barbara researchers and collaborators from campus biotech spinoff Integrated Biosciences, as well as Harvard, MIT ...

Microsoft's CEO, Satya Nadella, has announced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding ...

Revolution Medicines' proprietary data will train a bespoke version of NeuralPLexer, an AI model for protein-ligand ...

Pharmaceutical major Wockhardt Ltd. is going to shift its focus to drug discovery and biologics after exiting the US generics ...

Drug discovery startup Synfini Inc. said today it has closed on an $8.9 million expansion funding round led by JSL Health ...

Drug discovery efforts based on DNA-encoded chemical libraries are inadvertently overlooking numerous potential drug ...